Psych Congress

Psych Congress

October 26, 2018
2 min watch

VIDEO: Incorporating psychedelic research into mental health care

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact

ORLANDO, Fla. — In this video interview, Andrew Penn, RN, MS, NP, associate clinical professor at University of California, San Francisco, School of Nursing, discusses the session he presented at Psych Congress 2018, which offered an overview of three psychedelic medicines being used currently in psychiatric practice or in research.

During his presentation, Penn discussed the possibility of using ketamine as an adjunct to psychotherapy, MDMA-assisted psychotherapy for PTSD and psilocybin-assisted psychotherapy for MDD and/or treatment-resistant depression. He also talked about his experiences as a trainee working on psychedelic therapies and research.

Disclosure: Healio Psychiatry was unable to confirm any relevant financial disclosures at the time of publication.